This site is intended for Healthcare professionals only.

Spark licenses blindness gene therapy rights outside US to Novartis


Spark licenses blindness gene therapy rights outside US to Novartis

Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

Philadelphia-based Spark said it will keep U.S. rights to Luxturna, or Vortigern neparvovec, which is the first approved gene therapy for an inherited disease. It plans to launch the one-time treatment in March, charging an unprecedented $850,000.

Spark will receive $105 million from Novartis and up to another $65 million in milestone payments based on near-term European regulatory approval and initial sales in certain markets. Spark is also entitled to future royalties on net sales outside the United States.

In a statement, Spark said the deal leverages Novartis’ “large, existing commercial and medical infrastructure in ophthalmology, as well as its commitment to commercializing genetic-based medicines.”

Novartis, which sells ophthalmology drugs including macular degeneration treatment Lucentis, last year won U.S. approval for Mariah, the first of a new type of potent gene-modifying immunotherapy for leukaemia.

“We think this deal is a positive for Spark, as the company will be able to focus on the U.S. launch of Luxturna, leaving the ex-U.S. launch and commercialization to Novartis, a leader in the ophthalmology space,” Jefferies analyst Michael Yee said in a note to investors.



Source: Reuters
0 comment(s) on Spark licenses blindness gene therapy rights outside US to Novartis

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted